Evotec AG announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd., to identify small molecule modulators of various protein-protein interaction targets. Evotec will apply its proprietary and integrated fragment-based drug discovery platform ... more
Evotec receives first milestone in Roche biomarker collaboration
Evotec AG announced the successful achievement of a milestone in its biomarker alliance with Roche. The milestone was achieved on the decision by Roche to use a response prediction marker, identified using Evotec's Proteome Profiling platform, in an extended phase I oncology trial.
This is the first minor milestone achieved under the collaboration and licence agreement between Evotec and Roche, signed in 2011, which is part of the m4 Munich Biotech Cluster Personalized Medicine and Targeted Therapies initiative funded by the German Federal Ministry of Education and Research. Under the initial three-year term, Evotec and Roche conduct biomarker discovery and validation programmes for patient stratification in targeted cancer therapy. Evotec is eligible for further success-based payments upon clinical companion diagnostics development.
Dr Mario Polywka, Chief Operating Officer of Evotec AG, commented: "We are delighted with receiving this milestone and the first validation of our novel biomarker concept with Roche. I would like to thank everyone involved in the project to date for the fantastic science they have developed and for the hard work and determination to see it succeed in a clinical setting."
- companion diagnostics
- cancer therapy
Evotec AG announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Evotec will use its expertise and technologies in assay developme ... more
Evotec AG and DiscoveRx Corporation announced a co-marketing agreement for the screening of GPCR’s and other targets. Under the terms of the agreement, Evotec will have access to DiscoveRx’s PathHunter™ and cAMPHunter™ cell lines and proprietary EFC chemiluminescent detection technology f ... more
Roche announced that it has acquired Stratos Genomics, an early-stage sequencing technology company to advance the development of Roche’s nanopore sequencer. The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion (SBX™). The Roche nanopore sequen ... more
Roche announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the cobas® SARS-CoV-2 Test. It is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in nasopharyngeal and oropharyngeal swab sampl ... more
Roche announced it has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in blood. CAPP Med ... more
- 1Nano-sensor detects pesticides on fruit in minutes
- 2Most powerful dual-comb spectrometer developed
- 3AI identifies cancer cells
- 4On-site food freshness testing
- 5Lew lab sheds new light on cell membranes
- 6Inspiration for the laboratory of tomorrow
- 7‘E-nose’ sniffs out mixtures of volatile organic compounds
- 8Why are neuron axons long and spindly?
- 9High-speed imaging of microchips
- 10A free AI tool to quickly determine which protein labeling strategy works best for molecular interaction measurements